Click below to hear recorded Q&A audio for each question from our live webcast audience.
If an IGRA tests positive in someone who is immunocompromised, what are the next steps?
What next, if the QuantiFERON®-TB Gold/Plus was indeterminate in a 19-year-old with no risk factor? The screening for TB was necessary for adoption process. Should a T-SPOT®.TB test be ordered?
In foreign-born who have had BCG, do you recommend IGRAs across the board, or just for those who are immunocompromised?
What are the advantages of IGRA over TST when screening healthcare workers for latent TB?
Out of all of the examples of immunocompromised patients, should all of these types of immunocompromised patients be screened for TB, or only in certain situations?
Should someone who is PPD-positive be tested annually via QuantiFERON Gold or T-SPOT.TB test?
With regards to latent TB, specifically those with BCG vaccine, what are the repercussions? Or are there any?
You covered many examples of immunocompromised patients. Should all people identified with these risk factors be screened for TB, or just in certain situations?
T-SPOT is a registered trademark of Oxford Immunotec Ltd.
QuantiFERON is a registered trademark of the QIAGEN Group
About our Speaker
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Dr. Chemaly is a Professor of Medicine in the Department of Infectious Diseases, Infection Control & Employee Health at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chemaly is the Director of the Infection Control and the Antimicrobial Stewardship programs at MD Anderson Cancer Center. He heads the Viral Protection Ad Hoc Infection Control Subcommittee, and serves as Director of the Clinical Virology Research Program in the Department of Infectious Diseases.
Thank you for watching this on-demand webinar.
Oxford Immunotec is committed to providing medical education on an on-going basis.
If you have a suggested topic of interest please email: Ondemandeducation@oxfordimmunotec.com